Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Recruiting

Phase 3

PCV21Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Sponsor:

Sanofi Pasteur, a Sanofi Company

Code:

NCT06838000

Conditions

Pneumococcal Infections

Eligibility Criteria

Sex: All

Age: 7 - 17

Healthy Volunteers: Accepted

Interventions

PCV21

20vPCV

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-30. This information was provided to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company on 2025-08-13.